News for bluebird bio, Inc. (0HOH.L)

PR NewswireNEW YORK, Feb. 24, 2025 NEW YORK, Feb. 24, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following co

U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling more than 700 points on Friday. The Dow traded down 1.63% to 43,457.49 whi...

We recently compiled a list of the 10 Best Gene Therapy Stocks to Buy Right Now. In this article, we are going to take a look at where bluebird bio, Inc.

Gene therapy is referred to as a medical technique that involves modifying or manipulating genes to treat or prevent disease.

bluebird bio, Inc. (Nasdaq: BLUE) today announced new and updated data from LYFGENIAâ„¢ (lovotobegligene autotemcel, or lovo-cel) gene therapy for patients wit

bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Expositio

Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Ind

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.55%

Shares of Verint Systems Inc. VRNT rose sharply in today's pre-market trading after the company reported a year-over-year increase in third-quarter financial re...

bluebird bio, Inc. (NASDAQ: BLUE) (”œbluebird bio” or the ”œCompany”) today announced that it will proceed with a 1-for-20 reverse stock split (”œRevers

bluebird bio, Inc. (NASDAQ: BLUE) (”œbluebird bio”) today announced it has reached an agreement with the Center for Medicare and Medicaid Innovation to offe

bluebird bio, Inc. (NASDAQ:BLUE) Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ETCompany ParticipantsCourtney O'Leary - Director, Investor...

bluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter Results Call

Westford, USA, Sept. 12, 2024 (GLOBE NEWSWIRE) -- SkyQuest projects that the Global Gene Therapy Market will reach a value of USD 38.34 Billion by 2031,...

“CAR-T Cell Therapy Market” from 2024-2034 with covered segments By Drug Type (Ciloleucel, Axicabtagene, Brexucabtagene Autoleucel, Tisagenlecleucel, and...

Baron Health Care Fund declined in the second quarter of 2024, lagging its primary benchmark, the Russell 3000 Health Care Index.

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Genetic Engineering...

The Global Genome Editing Market Size was Valued at USD 7.75 Billion in 2023 and the Worldwide Genome Editing Market Size is Expected to Reach USD 34.75...

The Global CAR T-Cell Therapy Market Size was Valued at USD 4.29 Billion in 2023 and the Worldwide CAR T-Cell Therapy Market Size is Expected to Reach USD...